vs
BridgeBio Pharma, Inc.（BBIO）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
BRC Group Holdings, Inc.的季度营收约是BridgeBio Pharma, Inc.的1.2倍（$188.3M vs $154.2M），BRC Group Holdings, Inc.净利率更高（47.9% vs -126.2%，领先174.2%），BridgeBio Pharma, Inc.同比增速更快（2521.2% vs -21.9%）
本文提供的介绍实际对应 Brent Saunders 的个人履历，而非BridgeBio Pharma, Inc. 的企业信息。Brent Saunders是美国生物制药行业高管与企业家，目前担任博士伦公司董事长兼首席执行官，曾主导参与多起大型医药并购交易，同时涉足特殊目的收购公司领域，在医疗板块拥有丰富行业经验。
BBIO vs RILY — 直观对比
营收规模更大
RILY
是对方的1.2倍
$154.2M
营收增速更快
BBIO
高出2543.0%
-21.9%
净利率更高
RILY
高出174.2%
-126.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $154.2M | $188.3M |
| 净利润 | $-194.6M | $90.3M |
| 毛利率 | 94.7% | 79.5% |
| 营业利润率 | -90.5% | 32.3% |
| 净利率 | -126.2% | 47.9% |
| 营收同比 | 2521.2% | -21.9% |
| 净利润同比 | 27.2% | 1710.8% |
| 每股收益（稀释后） | $-1.00 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BBIORILY
| Q4 25 | $154.2M | $188.3M | ||
| Q3 25 | $120.7M | $215.3M | ||
| Q2 25 | $110.6M | $188.2M | ||
| Q1 25 | $116.6M | $197.2M | ||
| Q4 24 | — | $241.0M | ||
| Q3 24 | — | $225.5M | ||
| Q2 24 | — | $256.0M | ||
| Q1 24 | $211.1M | $263.4M |
净利润BBIORILY
| Q4 25 | $-194.6M | $90.3M | ||
| Q3 25 | $-184.9M | $91.1M | ||
| Q2 25 | $-183.8M | $139.5M | ||
| Q1 25 | $-169.6M | $-10.0M | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | — | $-284.4M | ||
| Q2 24 | — | $-433.6M | ||
| Q1 24 | $-36.2M | $-49.2M |
毛利率BBIORILY
| Q4 25 | 94.7% | 79.5% | ||
| Q3 25 | 94.6% | 83.7% | ||
| Q2 25 | 96.7% | 81.3% | ||
| Q1 25 | 97.7% | 81.4% | ||
| Q4 24 | — | 79.8% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | — | 84.5% | ||
| Q1 24 | 99.7% | 85.3% |
营业利润率BBIORILY
| Q4 25 | -90.5% | 32.3% | ||
| Q3 25 | -120.3% | 30.4% | ||
| Q2 25 | -121.4% | 5.7% | ||
| Q1 25 | -89.5% | -31.2% | ||
| Q4 24 | — | -69.2% | ||
| Q3 24 | — | -36.4% | ||
| Q2 24 | — | -90.8% | ||
| Q1 24 | 0.2% | -6.1% |
净利率BBIORILY
| Q4 25 | -126.2% | 47.9% | ||
| Q3 25 | -153.2% | 42.3% | ||
| Q2 25 | -166.2% | 74.1% | ||
| Q1 25 | -145.4% | -5.1% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | — | -126.1% | ||
| Q2 24 | — | -169.4% | ||
| Q1 24 | -17.1% | -18.7% |
每股收益（稀释后）BBIORILY
| Q4 25 | $-1.00 | $2.78 | ||
| Q3 25 | $-0.95 | $2.91 | ||
| Q2 25 | $-0.95 | $4.50 | ||
| Q1 25 | $-0.88 | $-0.39 | ||
| Q4 24 | — | $-0.01 | ||
| Q3 24 | — | $-9.39 | ||
| Q2 24 | — | $-14.35 | ||
| Q1 24 | $-0.20 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $570.1M | $226.6M |
| 总债务越低越好 | $2.0B | $1.4B |
| 股东权益账面价值 | $-2.1B | $-171.5M |
| 总资产 | $936.0M | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BBIORILY
| Q4 25 | $570.1M | $226.6M | ||
| Q3 25 | $643.0M | $184.2M | ||
| Q2 25 | $756.9M | $267.4M | ||
| Q1 25 | $540.6M | $138.3M | ||
| Q4 24 | — | $146.9M | ||
| Q3 24 | — | $159.2M | ||
| Q2 24 | — | $236.9M | ||
| Q1 24 | $519.7M | $190.7M |
总债务BBIORILY
| Q4 25 | $2.0B | $1.4B | ||
| Q3 25 | $2.0B | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BBIORILY
| Q4 25 | $-2.1B | $-171.5M | ||
| Q3 25 | $-1.9B | $-260.5M | ||
| Q2 25 | $-1.8B | $-351.7M | ||
| Q1 25 | $-1.6B | $-496.8M | ||
| Q4 24 | — | $-488.2M | ||
| Q3 24 | — | $-497.6M | ||
| Q2 24 | — | $-218.3M | ||
| Q1 24 | $-1.0B | $228.4M |
总资产BBIORILY
| Q4 25 | $936.0M | $1.7B | ||
| Q3 25 | $998.3M | $1.7B | ||
| Q2 25 | $1.1B | $1.5B | ||
| Q1 25 | $881.6M | $1.5B | ||
| Q4 24 | — | $1.8B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $3.2B | ||
| Q1 24 | $849.3M | $5.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-56.4M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $-56.5M | — |
| 自由现金流率自由现金流/营收 | -36.6% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | 0.29× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BBIORILY
| Q4 25 | $-56.4M | $26.2M | ||
| Q3 25 | $-109.6M | $-60.6M | ||
| Q2 25 | $-80.7M | $-25.6M | ||
| Q1 25 | $-199.2M | $184.0K | ||
| Q4 24 | — | $-2.7M | ||
| Q3 24 | — | $19.5M | ||
| Q2 24 | — | $111.5M | ||
| Q1 24 | $-219.5M | $135.4M |
自由现金流BBIORILY
| Q4 25 | $-56.5M | — | ||
| Q3 25 | $-110.0M | — | ||
| Q2 25 | $-81.3M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-220.2M | — |
自由现金流率BBIORILY
| Q4 25 | -36.6% | — | ||
| Q3 25 | -91.2% | — | ||
| Q2 25 | -73.5% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -104.3% | — |
资本支出强度BBIORILY
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.3% | — |
现金转化率BBIORILY
| Q4 25 | — | 0.29× | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BBIO
暂无分部数据
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
